Home › Funds › Bain Capital Life Sciences Investors, LLC › DNTH

Bain Capital Life Sciences Investors, LLC position in DNTH

DIANTHUS THERAPEUTICS INC COM · Health Care

Bain Capital Life Sciences Investors, LLC reported holding 362,470 shares of DNTH (DIANTHUS THERAPEUTICS INC COM) in its Q2 2026 13F filing — a position valued at US$35.3M, representing 2.10% of its reported portfolio and ranking #12 among its reported holdings. Bain Capital Life Sciences Investors, LLC has disclosed DNTH holdings in 10 of the last 10 reported quarters, going back to Q1 2024.

Latest position (Q2 2026)362.47K sh
Reported value held$35.33M
Portfolio Weight2.10%
First reportedQ1 2024
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Bain Capital Life Sciences Investors, LLC's DNTH position evolved

Bain Capital Life Sciences Investors, LLC first disclosed a stake in DNTH in Q1 2024 at 2,992,028 shares (US$89.8M). Across 10 filings, Bain Capital Life Sciences Investors, LLC increased the stake 1 time(s), trimmed it 5 time(s) and left it unchanged 3 time(s). The most recent filing (Q2 2026) shows 362,470 shares valued at US$35.3M. Notable position changes include a 47% trim in Q3 2025 (shares rose 5% over the following quarter), a 43% trim in Q4 2025 (shares rose 104% over the following quarter), a 51% trim in Q1 2026 (shares rose 16% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2024 2.99M $89.76M New
Q2 2024 3.01M $77.99M Add
Q3 2024 3.01M $82.51M Hold
Q4 2024 2.69M $58.64M Reduce
Q1 2025 2.69M $48.79M Hold
Q2 2025 2.48M $46.24M Reduce
Q3 2025 1.32M $51.78M Reduce
Q4 2025 743.59K $30.64M Reduce
Q1 2026 362.47K $30.42M Reduce
Q2 2026 362.47K $35.33M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About DNTH and 13F data

DNTH (DIANTHUS THERAPEUTICS INC COM) is a Health Care company. 72 other funds we track also report a position in DNTH — the largest reported positions include Fairmount Funds Management LLC (US$247.3M), Avidity Partners Management LP (US$205.1M), Octagon Capital Advisors LP (US$179.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding DNTH

All DNTH fund holders →

FAQ

How long has Bain Capital Life Sciences Investors, LLC held DNTH?

Bain Capital Life Sciences Investors, LLC has disclosed DNTH holdings in 10 of the last 10 reported quarters, going back to Q1 2024.

What is Bain Capital Life Sciences Investors, LLC's current position in DNTH?

As of Q2 2026, Bain Capital Life Sciences Investors, LLC holds 362.47K shares of DNTH (DIANTHUS THERAPEUTICS INC COM), valued at $35.33M, representing 2.10% of its reported portfolio and ranking #12.

Has Bain Capital Life Sciences Investors, LLC been buying or selling DNTH?

In the latest 13F filing (Q2 2026), Bain Capital Life Sciences Investors, LLC held unchanged its position in DNTH.

Which other funds hold DNTH?

Other major institutional holders of DNTH include Fairmount Funds Management LLC, Avidity Partners Management LP, Octagon Capital Advisors LP, among 72 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.